MEI Pharma Granted U.S. Patent #11723893: Isoflavonoid compositions and methods for the treatment of cancer
Portfolio Pulse from Charles Gross
MEI Pharma has been granted U.S. Patent #11723893 for isoflavonoid compositions and methods for the treatment of cancer. This could potentially strengthen the company's intellectual property portfolio and provide a competitive edge in the oncology market.
August 15, 2023 | 1:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The new patent could potentially enhance MEI Pharma's intellectual property portfolio and provide a competitive advantage in the oncology market.
Patents provide exclusive rights to the patent holder, which can prevent competitors from copying, manufacturing, selling, or importing the patented invention. This could potentially lead to increased market share and revenues for MEI Pharma, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100